Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus tacrolimus in primary membranous nephropathy
CTR20210974Phase 3Active
- Sponsor
- Roche
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in idiopathic membranous glomerulonephritis (IMG), sponsored by Roche. Started Aug 2021; status: active.
02
Drugs
obinutuzumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20210974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210974.